AIM
COGT icon

ABS Investment Management’s Cogent Biosciences COGT Stock Holding History

ABS Investment Management’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$182K Buy
+39
New +$1.36K 0.11% 98

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ABS Investment Management's COGT Position: Q2 2026 in Review

ABS Investment Management opened a new position in Cogent Biosciences (COGT) in Q2 2026: 39 shares worth $182K. The stake represents 0.11% of the portfolio and ranks #98 among its holdings.

290 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

  • ABS Investment Management held 39 shares of Cogent Biosciences worth $182K as of Q2 2026.
  • Cogent Biosciences was a new ABS Investment Management position in Q2 2026.
  • Cogent Biosciences made up 0.11% of ABS Investment Management's portfolio in Q2 2026, its #98 holding.
  • 290 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on ABS Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.